Inflammation in mood disorders: a new day or a false dawn?

The involvement of inflammatory mechanisms may one day help us to identify biological subtypes of mood disorders and so tailor treatment more effectively to individual needs. However, the biology is likely to be highly complex. While the treatment of mood disorders with agents that can broadly be described as anti-inflammatory has shown some preliminary evidence of effect, a high degree of caution is warranted moving forward.

Mood disorders contribute greatly to the global burden of disease, as measured by years lost to premature mortality and disability: in 2017, unipolar depressive disorders and bipolar affective disorder were both among the top ten conditions responsible for overall disease burden.1

Presentation

Inflammation in mood disorders: a new day or a false dawn?

1 / 8
The burden associated with depression is large and increasing
Referencias
  1. Ratnasingham S et al. Opening Eyes, Opening Minds: The Ontario Burden of Mental Illness and Addictions Report. Institute for Clinical Evaluative Sciences and Public Health Ontario, 2012
  2. Wittchen HU et al. Eur Neuropsychopharmacol 2011;21:655-79.
     
1 / 8
Depression is the most burdensome disorder of all brain diseases in the EU
Slide information
Referencias

The DALY is a health gap measure for burden of disease, capturing both years of life lost due to premature mortality and years of life lost due to living with disability. Overall, the burden of disease in mental and other disorders of the brain is mainly due to disability, i.e., these disorders impact on the daily functioning of people, rather than leading to premature mortality compared to cancer or cardiovascular disorders.

In the EU, mental and other disorders of the brain are responsible for a huge proportion of overall burden of disease: almost 1 in 3 of all years of life lost due to premature mortality in women, and almost 1 in 4 in men are due to disorders of the brain. 

The three most important contributors to burden of disease are depression (7.2% of the overall burden of disease in Europe), Alzheimer's disease/dementia (3.7%) and alcohol use disorders (3.4%). There are clear gender differences: women were disproportionally affected by depression (one in 10 healthy years of life lost is due to this disorder, or 10.3% of all the DALYs), while for men alcohol use disorders are the biggest relative contributor to the disease burden in Europe (5.3% of all the DALYs).

  1. Wittchen, H.-U. et al, 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur. Neuropsychopharmacology (2011) 21, 655–679
1 / 8
Depression has detrimental effects on overall health
Referencias

Adapted from Moussavi S et al. Lancet. 2007;370:851-8.

1 / 8
Depression is associated with significant personal and societal consequences
Referencias
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013
  2. Krol M, et al. Pharmacoeconomics. 2011;29(7):601–19
  3. Marcus M, et al. 2012. http://www.who.int/mental_health/management/depression/who_paper_depress... Accessed April 16, 2014.
     
1 / 8
The personal burden of MDD can be significant and wide-ranging
Referencias
  1. Kessler RC. Psychiatr Clin North Am 2012;35(1):1-14.
1 / 8
MDD has significant costs to society
Slide information
Referencias

This slide illustrates the global social burden of MDD. The data is based on a systematic review of epidemiological data by Ferrari et al 2013. For this; data was pooled using a Bayesian meta-regression. These weights were used to calculate years lived with disability (YLDs) and disability adjusted life years (DALYs). Separate DALYs were estimated for suicide and ischemic heart disease attributable to depressive disorders.

Country data for key countries also exist.

  1. World Health Organization (WHO). Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. 2011. http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf. Accessed June 2015
  2. WHO. The Global Burden of Disease 2004 Update. http://www.who.int/healthinfo/global_burden_dis ease/2004_report_update/en/. Accessed July 2015 
  3. Ferrari AJ et al. PLoS Medi 2013;10:e1001547
1 / 8
MDD has significant costs to society: EU
Slide information
Referencias

This slide illustrates European burden of MDD with a focus on costs inferred due to impact on work. 

Note that: 
Absenteeism = lost days of work
Presenteeism = low performance while at work, which is transformed into lost day equivalents

  1. Hughes S. MEP: Depression in the Workplace. http://www.enwhp.org/fileadmin/user_upload/pdf/Policy_recommendations_de.... Accessed July 2015
1 / 8
Depression is associated with significant economic costs
Referencias
  1. Collins PY et al. Nature. 2011;475:27-30
  2. Sobocki P et al. J Ment Health Policy Econ. 2006;9:87-98
  3. Stewart WF et al. JAMA. 2003; 289:3135-44; 
  4. World Health Organization. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004updat... = 1. Accessed June 2016 

View and download these and other slides on the Epidemiology and Burden of Major Depressive Disorder here.

Treatment options encompass a range of non-pharmacological and pharmacological therapies. In a major recent systematic review and meta-analysis, Andrea Cipriani et al reinforced the view that anti-depressant drugs are effective in major depressive disorder (MDD) when compared to placebo.2 However, many patients do not respond, or respond only partially. If we define adequate clinical response as a 50% or greater decrease on an established rating scale, around half of patients with MDD do not achieve an adequate response3,4 ; and many of those who do experience benefit subsequently relapse. 

A recent review has emphasized the importance of urgent intervention in MDD, treatment aimed at full functional recovery, a patient-centered approach to setting goals, use of interventions tailored to the circumstances of the individual, and systematic monitoring of efficacy.4 It is estimated that MDD is treatment-resistant – in that it has not responded to two lines of therapy involving either a switch in agent or adjunctive therapy – in around a third of patients.5

Categorizing MDD as a single entity does not fit with the reality of diagnosis, clinical experience, or – probably – underlying biology

Heterogeneity in MDD

Part of the problem lies in the fact that we categorize MDD as a single entity. This does not fit with the reality of diagnosis, which can be based on many different symptom combinations.  A recent study of Korean patients found that more than a hundred different combinations of symptoms fulfilled the DSM-IV criteria for MDD.6 Nine different combinations were present in more than 3% of patients. This study complements the demonstration by Zimmerman et al7 that more than a hundred symptom combinations were present among US patients with MDD.

Depression is heterogeneous, and in fact many different disorders. In treatment, antidepressants are often effective. But there are patients who are resistant, and as a group need extra help.

Moreover, the idea that MDD is a single entity does not align with our clinical experience of disease heterogeneity. Nor does it conform with growing hints from biology which suggest diverse causal mechanisms. 

 

Presentation

Inflammation in mood disorders: a new day or a false dawn?

1 / 8
Depression is a clinically heterogeneous disorder
Referencias
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013
  2. Marazziti D et al. Eur J Pharmacol 2010;626(1):83–86
  3. Hammar A, Ardal G. Front Hum Neurosci 2009;3:26. doi: 10.3389/neuro.09.026.2009
  4. Fehnel SE et al. CNS Spectr 2013;21:43–52. 
  5. Jaeger J et al. Psychiatry Res 2006;145:39–48
  6. World Health Organization Depression Fact Sheet N369. http://www.who.int/mediacentre/factsheets/fs369/en/#. Accessed August 2015

View and download this and other slides on the Definitions and Diagnosis of Major Depressive Disorder here.

Biomarkers may help tailor therapy to individuals and better understand treatment response and resistance

Akil et al  emphasize the need for biomarkers that may help us tailor therapy to individual circumstances and better understand reasons for treatment response and resistance.8 They have recently reported progress – aided by animal models, functional imaging studies, and postmortem examination of the human brain – in identifying specific abnormalities of neural circuitry that may underlie different forms of depression. Dysfunctional corticolimbic circuitry in the forebrain is implicated.8 There is also ongoing work to reveal associated changes in gene expression, particularly those related to the stress response.

Such an approach is entirely consistent with that of Thomas Insel who in 2013 suggested that improving outcome in depression will require the bringing together of “genetic, imaging, physiologic and cognitive data to see how all the data – not just the symptoms – cluster, and how these clusters relate to treatment response.”9 Dr. Insel’s Research Domains – based on systems mediating negative valence, positive valence, cognition, social processes, and modulation of arousal – are proposed as a means of aligning symptomatology with biology across conventional diagnostic categories.

It is in essence a call for psychiatry to emulate oncology’s efforts towards precision medicine. Even within a specific tumor type, segmentation of cancer patients into those with specific molecular mutations has been the key to developing the targeted therapies that have brought major advances in disease-free and overall survival.

The remainder of this paper considers one specific potentially causal mechanism – inflammation – that has attracted considerable recent interest as a factor that may underlie the development and maintenance of mood disorders in at least some of our patients.

Mean CRP in treatment-resistant patients was significantly greater than in healthy controls

Inflammatory mediators: risk factor and possible biomarker for response or resistance

Among others, the work of Professor Ed Bullmore (University of Cambridge, UK) and colleagues has focused attention on inflammation as a risk factor for depression. Most recently, he and coworkers assayed levels of C-reactive protein (CRP) in the peripheral blood of 102 people with MDD who were treatment-resistant and currently experiencing depression, 48 patients with MDD who were treatment-responsive with no current depression, 48 depressed people receiving no antidepressant medication, and 54 healthy controls.10 Levels were corrected for body mass index.

There were no statistically significant differences from controls in treatment-responsive and untreated MDD groups. CRP level also appeared to be associated with clinical phenotype – notably the presence of vegetative symptoms of depression and state anxiety – and with etiology, in this case childhood adversity.

Association or causation?

Such findings reveal an association between depression and a major marker of inflammation. They do not establish causation. However, a number of plausible mechanisms might underlie a causal link. These include the effects of chronically elevated stress hormones such as cortisol, the creation of neurotoxic molecules, and disruption of neurotransmitter metabolism.11,12

One problem in investigating a potentially causal connection has been the difficulty in establishing chronic exposure to stress hormones among people in whom the development of MDD has been a long-term process. Herane Vives et al have addressed this problem by looking at cortisol concentration in hair.11  In a review of studies that used this promising technique, they found replicable increases in hair cortisol associated with stressful life events. More importantly in the context of this paper, they also found some evidence of chronically raised cortisol levels in the hair of people with MDD, compatible with an etiological role for hypercortisolemia.

Cortisol concentration in hair reflects chronic stress exposure

In an earlier review, Licinio and Wong12 argue in support of a role for inflammatory processes that they say are compatible with the waxing and waning course of depression, and that would account for the association between depression and comorbidities such as ischemic heart disease. More specifically, Licinio and Wong argue for the role of interleukin-1beta and IL-1 receptor antagonist in the biology of major depression, and also – potentially – in the effects of antidepressant treatment.

That said, proponents of the idea of a causal relationship point out that evidence is inconsistent across studies and that much of it is retrospective. In an attempt to cast further light on the connection, Bullmore et al recently undertook a prospective study involving the English Longitudinal Study of Aging.13

Results showed that repeated exposure to systemic inflammation (as indicated by number of occasions with C-reactive protein ⩾3 mg l-1) was associated with the development of depressive symptoms among women. When compared with women who had experienced no episodes of inflammation, those with two episodes were more than twice as likely to develop depressive symptoms. However, there was no such association among men; and the authors acknowledge the need for their finding among women to be replicated. 

It must also be noted that peripheral markers of inflammation may bear little relationship to what is happening in the brain. However, evidence of clinical benefit from the use of anti-inflammatory agents would greatly strengthen the case for the causal role of inflammation – whether central or peripheral.

Evidence from randomized controlled trials (RCTs)

In a systematic review of studies published prior to 2014, Köhler et al identified fourteen RCTs (involving more than six thousand subjects) which had investigated the efficacy of anti-inflammatory agents in patients with depression or depressive symptoms.14 In ten trials, the agents used were nonsteroidal anti-inflammatory drugs (NSAIDs) and in four trials cytokine inhibitors.

There is preliminary evidence high levels of inflammatory markers may predict response to antidepressants and lack of response to CBT

Overall, active treatment was more effective than placebo both in patients with depression and in those with depressive symptoms. Sub-analysis suggested the potential antidepressant value, in particular, of the cyclo-oxygenase 2 inhibitor celecoxib. However, the authors caution that the RCTs included in the systematic review overall had a high-risk of bias “owing to potentially compromised internal validity”.

Meta-analyses of anti-inflammatory agent RCTs in MDD suggest need for further trials

Husain and colleagues also recently carried out a meta-analysis, this time including studies of bipolar as well as unipolar depression.15  Compared with controls (who received placebo or treatment as usual), patients receiving anti-inflammatory treatment (using agents with different mechanisms of action) had significantly lower post-treatment depression scores.

Active intervention was also significantly more effective than control in reducing post-treatment scores for manic symptoms. But anti-inflammatory treatment did not achieve significantly greater reduction in symptom scores from baseline to post-treatment assessment. And the authors concluded that routine anti-inflammatory treatment for mood disorders could not be routinely recommended until further high-quality studies had shown a positive effect.

The case for the relevance of inflammatory mediators would also be strengthened by evidence that inflammatory markers might predict response or resistance to antidepressant treatment in general.

Inflammation in mood disorders

  • Both MDD and bipolar disorders are heterogeneous conditions
  • Developing a personalized approach to management is challenging
  • Treatment resistant depression has been defined empirically by lack of response
  • The presence of inflammatory markers may contribute to the subtyping of mood disorders, but the biology is likely to be very complex
  • “Anti-inflammatory” agents show a signal of efficacy in a preliminary meta-analysis, albeit with diverse agents; and there is a need for further studies
Presentation

Inflammation in mood disorders: a new day or a false dawn?

1 / 8
Neuroinflammation
Slide information
Referencias

Neuroinflammation is simply the natural brain response to injury, infection, or disease.[Hurley & Tizabi, 2013] Inflammation is initiated and controlled by white blood cells in the body, but in the central nervous system (CNS) neuroinflammation is mediated principally by microglia.[Hurley & Tizabi, 2013] The microglial cells patrol the CNS, monitoring for signs of injury or infection.[Hurley & Tizabi, 2013] Activation of glial cells quickly leads to the release of both pro- and anti-inflammatory cytokines (see the next slide for more detail about the links between these immune system signalling molecules and depression).[Hurley & Tizabi, 2013] The final effect of glial activation is dependent on the balance between opposing responses; it has been suggested that glial activation initially serves a protective function, but that continuous activation can lead to exaggerated release of proinflammatory cytokines, and neuronal damage.[Hurley & Tizabi, 2013] As stated on the slide, the problem is showing the directionality of the link between depression and neuroinflammation.[Brites & Fernandes, 2015]

Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration and depression. Neurotox Res 2013; 23 (2): 131–144.

Brites D, Fernandes A. Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. Front Cell Neurosci 2015; 9: 476.

Kempton MJ, Salvador Z, Munafò MR, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011; 68 (7): 675–690

View and download this and other slides on the Neurobiology and aetiology of Major Depressive Disorder here.

In a meta-analysis, Strawbridge et al included data from 35 studies that allowed clinical response to antidepressant treatment to be related to levels of the inflammatory markers IL-6, TNFα and CRP.16 Regardless of clinical outcome, levels of IL-6 decreased with treatment.

However, treatment resistance was associated with high levels of TNFα that persisted during therapy. There was a strong trend towards higher baseline inflammation – using a composite of inflammatory markers – being associated with non-response. The authors interpreted their findings as suggesting that elevated levels of inflammation contribute to treatment resistance.

Discussion

In addition to the evidence cited above suggesting a relationship between inflammatory markers and treatment response and resistance, Leighton et al argue that the association between inflammatory diseases and depression makes some element of common etiology plausible, that data from preclinical studies provide evidence that chemokines are linked with peripheral-central crosstalk, and that chemokine-related dysfunction of the hypothalamic–pituitary–adrenal axis and of neurotransmitters may be involved in pathogenesis of the disease.17 

If future work clearly establishes that people with depression can be classified according to their profile of inflammatory markers such as chemokines, and that such profiles have implications for the success or otherwise of different forms of therapy, this will mark a major advance.

Such a possibility would be particularly valuable if a specific inflammatory profile could be used to increase understanding of treatment-resistant disease. However, for the present, data indicating an association between inflammation on the one hand and depression etiology and outcome on the other should be considered more as hypothesis-generating than as a guide to management.

Acknowledgement

We thank Professor Allan Young for sharing his expertise around inflammation in mood disorders and for providing feedback in the development of this article.

Referencias
  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858.
  2. Cipriani A, Furukawa TA, Salanti G et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
  3. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.Eur J Neuropsychopharmacol 2009;19:34-40.
  4. Oluboka OJ, Katzman MA, Habert J et al. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2018;21:128–144
  5. Gaynes BN, Warden D, Trivedi MH et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-45.
  6. Park SC, Kim JM, Jun TY et al. How many different symptom combinations fulfil the diagnostic criteria for major depressive disorder? Results from the CRESCEND study. Nord J Psychiatry 2017;71:217-222.
  7. Zimmerman M, Ellison W, Young D et al. How many different ways do patients meet the diagnostic criteria for major depressive disorder? Compr Psychiatry 2015;56:29-34.
  8. Akil H, Gordon J, Hen R et al. Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272-288.
  9. https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/transfor...
  10. Chamberlain SR, Cavanagh J, de Boer P et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019 Jan;214(1):11-19.
  11. Herane Vives A, De Angel V, Papadopoulos A, et al.  The relationship between cortisol, stress and psychiatric illness: New insights using hair analysis. J Psychiatr Res. 2015 Nov;70:38-49.  
  12. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4(4):317-27.
  13. Bell JA, Kivimäki M, Bullmore ET, Steptoe A; MRC ImmunoPsychiatry Consortium, Carvalho LA. Repeated exposure to systemic inflammation and risk of new depressive symptoms among older adults. Transl Psychiatry. 2017 Aug 15;7(8) 
  14. Köhler O, Benros ME, Nordentoft M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-91.
  15. Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1137-1148. 
  16. Strawbridge R, Arnone D, Danese A et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532-43.
  17. Leighton SP, Nerurkar L, Krishnadas R et al. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Molecular Psychiatry 2018; 23: 48–5
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country